These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29300270)

  • 1. 18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
    Hall DO; Hooper CE; Searle J; Darby M; White P; Harvey JE; Braybrooke JP; Maskell NA; Masani V; Lyburn ID
    Nucl Med Commun; 2018 Feb; 39(2):161-170. PubMed ID: 29300270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
    Incerti E; Broggi S; Fodor A; Cuzzocrea M; Samanes Gajate AM; Mapelli P; Fiorino C; Dell'Oca I; Pasetti M; Cattaneo M; Calandrino R; Gianolli L; Di Muzio N; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2071-2078. PubMed ID: 29876617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of pretreatment volume-based quantitative
    Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
    Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
    Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive role of [
    Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
    AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y; Takuwa T; Miyata Y; Fukuoka K; Hasegawa S; Nakano T; Okada M
    Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of
    Söyler Y; Özmen Ö; Kabalak PA; Ertürk H; Uğurman F; Yılmaz Ü
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(1):3-9. PubMed ID: 36152987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loco-regional staging of malignant pleural mesothelioma by integrated
    Murphy DJ; Mak SM; Mallia A; Jeljeli S; Stirling JJ; Goh V; Bille A; Cook GJR
    Eur J Radiol; 2019 Jun; 115():46-52. PubMed ID: 31084758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
    Klabatsa A; Chicklore S; Barrington SF; Goh V; Lang-Lazdunski L; Cook GJ
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):276-82. PubMed ID: 24057459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
    Schaarschmidt BM; Sawicki LM; Gomez B; Grueneisen J; Hoiczyk M; Heusch P; Buchbender C
    Clin Imaging; 2016; 40(5):956-60. PubMed ID: 27232931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
    Kitajima K; Doi H; Kuribayashi K
    Jpn J Radiol; 2016 Aug; 34(8):537-47. PubMed ID: 27222020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - A prospective cohort study.
    May IJ; Nowak AK; Francis RJ; Ebert MA; Dhaliwal SS
    J Med Imaging Radiat Oncol; 2024 Feb; 68(1):57-66. PubMed ID: 37898984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
    Gudmundsson E; Labby Z; Straus CM; Sensakovic WF; Li F; Rose B; Cunliffe A; Kindler HL; Armato SG
    Eur Radiol; 2019 Feb; 29(2):682-688. PubMed ID: 29967955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Niccoli Asabella A; Di Palo A; Altini C; Fanelli M; Ferrari C; Lavelli V; Ranieri G; Gadaleta CD; Rubini G
    Hell J Nucl Med; 2018; 21(3):191-197. PubMed ID: 30411729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
    Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
    J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric cancer and image-derived quantitative parameters: Part 2-a critical review of DCE-MRI and
    Tang L; Wang XJ; Baba H; Giganti F
    Eur Radiol; 2020 Jan; 30(1):247-260. PubMed ID: 31392480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.